RenovoRx (RNXT) Earnings Date & Reports

Key Takeaways

• RenovoRx reported record third quarter 2026 revenue of approximately $1.07 million, up roughly 17% sequentially and more than four times the $266,000 recorded a year earlier.
• Net loss per share was $0.08, in line with the $0.08 loss reported in the prior-year quarter and slightly below the consensus estimate of a $0.07 loss.
• Management maintained its full-year 2026 revenue guidance of $3.75 million to $4.25 million, implying year-over-year growth of roughly 241% to 286%.
• Cash and cash equivalents stood at approximately $10.4 million, which the company expects to fund operations into the second half of 2027.
• The commercial footprint continued to expand, with active cancer centers growing from 21 to 26 and the total commercial funnel surpassing 65 centers.
• For more detail on RenovoRx's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for timely updates and analysis.
• To discover AI-driven trading ideas and market opportunities, explore Trending AI Robots.

Earnings Context and Why It Matters

RenovoRx, a life sciences company commercializing the FDA-cleared RenovoCath drug-delivery device, is at an inflection point between its early commercialization ramp and its pivotal clinical program. The third quarter marked the company's first time exceeding $1 million in quarterly revenue, a milestone that signals growing adoption of its Trans-Arterial Micro-Perfusion (TAMP) platform for difficult-to-treat tumors such as locally advanced pancreatic cancer. With the Phase III TIGeR-PaC trial fully enrolled and top-line data expected in the second half of 2027, investors are closely watching whether the commercial business can scale while clinical catalysts approach. This report offers a key read on demand momentum, margin quality, and the durability of the company's cash runway.

Reported Results

For the third quarter ended September 30, 2026, RenovoRx reported record revenue of approximately $1.07 million, compared with $266,000 in the same period of 2025. Gross profit was $878,000, reflecting a gross margin of roughly 82%. Research and development expenses were approximately $1.2 million, down from $1.7 million a year earlier, while selling, general, and administrative expenses rose to approximately $2.9 million from $1.7 million as the company invested in its commercial infrastructure. Loss from operations was approximately $3.2 million, essentially unchanged year over year, and net loss per share was $0.08, matching the prior-year figure.

Relative to expectations, revenue was broadly in line with the consensus estimate of roughly $1.06 million, while the $0.08 net loss per share came in modestly below the consensus estimate of a $0.07 loss. The company reiterated its full-year 2026 revenue guidance of $3.75 million to $4.25 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for those monitoring earnings-driven moves in names like RenovoRx. Explore the AI Screener to streamline your research and surface relevant opportunities.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around RenovoRx reflected growing optimism about its commercial ramp, supported by the company's Q2 revenue beat and its raised full-year outlook. The record third-quarter revenue reinforces the narrative of accelerating adoption, even as the slight earnings miss and ongoing operating losses remind investors that the company remains pre-profitability. Post-earnings attention has centered on the pace of commercial center activation, the stability of gross margins above 80%, and the strength of the balance sheet, which management indicates is sufficient to fund operations into the second half of 2027. Key risk factors include the lumpiness of early-stage device revenue and execution on the company's target of expanding its active center network through year-end.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will watch whether RenovoRx can sustain its commercial momentum and convert its growing pipeline of more than 65 centers into active, revenue-generating accounts. Management has signaled confidence by reaffirming its 2026 revenue guidance, and the fourth quarter will be a key test of that trajectory.

On the clinical front, the completed enrollment of the Phase III TIGeR-PaC trial positions the company for a top-line data readout expected in the second half of 2027. That catalyst has the potential to meaningfully reshape the investment case by providing evidence on survival, safety, and tolerability for its targeted chemotherapy delivery approach.

Investors should also monitor cost trends, particularly selling, general, and administrative expenses tied to the commercial buildout, as well as gross margin stability. The company's path to cash-flow breakeven, previously framed around a $5 million quarterly revenue run rate, will be an important indicator of operating leverage as adoption scales.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations